



CircularLRRC7 is a Potential Tumor Suppressor Associated With miR-1281 and PDXP Expression in Glioblastoma

Xue Kong^{1,2,3,4†}, Ruiting Xu^{4†}, Wei Wang^{3,4†}, Minghui Zeng⁵, Yuan Li⁴, Mengyu Lin⁴, Wenchao Zhou^{4*}, Xianming Fu^{1,2,5*} and Haibo Wu^{3,4*}

¹School of Medicine, Shandong University, Jinan, China, ²Department of Neurosurgery, Anhui Provincial Hospital, Shandong University, Hefei, China, ³Department of Pathology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China, ⁴Intelligent Pathology Institute, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China, ⁵Department of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

OPEN ACCESS

Edited by:

Binod Kumar,
Loyola University Chicago,
United States

Reviewed by:

Crismita Dmello,
Northwestern University,
United States
Fubing Wang,
Wuhan University, China
Ronald Benjamin,
University of California, San Francisco,
United States

*Correspondence:

Haibo Wu
wuhaibo@ustc.edu.cn
Xianming Fu
fuxianmingah@163.com
Wenchao Zhou
wzaz@ustc.edu.cn

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Molecular Diagnostics and
Therapeutics,
a section of the journal
Frontiers in Molecular Biosciences

Received: 18 July 2021

Accepted: 09 November 2021

Published: 29 November 2021

Citation:

Kong X, Xu R, Wang W, Zeng M, Li Y,
Lin M, Zhou W, Fu X and Wu H (2021)
CircularLRRC7 is a Potential Tumor
Suppressor Associated With miR-
1281 and PDXP Expression
in Glioblastoma.
Front. Mol. Biosci. 8:743417.
doi: 10.3389/fmolb.2021.743417

Circular RNAs (circRNAs) are usually enriched in neural tissues, yet about 80% circRNAs have lower expression in gliomas relative to normal brains, highlighting the importance of circRNAs as tumor suppressors. However, the clinical impact as well as the pathways regulated by the tumor-suppressive circRNAs remain largely unknown in glioblastoma (GBM). Through bioinformatic analysis followed by experimental validation, we found that hsa_circ_0114014 (circLRRC7) was dramatically down-regulated in GBM when compared with normal brain tissues ($p < 0.0001$). GBM patients with a lower circLRRC7 expression had poorer progression-free survival (PFS, $p < 0.05$) and overall survival (OS, $p < 0.05$). Analyses of the predicted target miRNAs of circLRRC7 in CSCD and CRI databases, in combination with the miRNA expression data in GBMs and normal brains from GSE database, revealed miR-1281 as a potential downstream target of circLRRC7. Subsequently, the target genes of hsa-mir-1281 were predicted by TargetScan, miRDB and miRNATAR databases. Intersection analysis and correlation test indicated that PDXP was a potential target of miR-1281. In summary, circLRRC7 may be a tumor suppressor that associated with miR-1281 and PDXP expression in GBM, which may provide novel therapeutic targets for GBM treatment.

Keywords: circRNA, hsa_circ-0114014, GBM, miRNA, miR-1281, PDXP, tumor suppressor

INTRODUCTION

GBM (glioblastoma multiforme) is the most malignant brain tumor with the highest mortality rate (5-years survival rate 3–5%) and shortest median survival period (approximately 1.4-years) (Van Meir et al., 2010). Radical surgery combined with concomitant chemoradiation therapy based on temozolomide is still the primary treatment strategy for GBM which has been used for over 2 decades. Although the antiangiogenic drug bevacizumab was approved for patients with recurrent GBM, there's little or no improvement in patients' overall survival (Ameratunga et al., 2018). These facts urge the investigation of new therapeutics for GBM treatment.

Circular RNAs (circRNAs) are a group of novel RNA molecules with covalently closed loop that generally exist in eukaryotes (HSU and Coca prados, 1979; Jeck et al., 2013). Highly conserved among species, circRNAs have tissue-specific expression and are especially enriched in neuronal tissues

TABLE 1 | The primers of circular RNAs.

Circular RNA	Forward primer	Reverse primer
hsa_circ_0073237	GCAGCATCAGAACAGCAAGT	TCACTCATTGACCTGGTAAAT
hsa_circ_0024085	ATCTTCTCAGCCTGCCAAT	GGAACCCCTGGAGCTGTCT
hsa_circ_0009027	GGGCCTACACCTCGAATCC	CTTGTCCCTTGTGTGCTGGC
hsa_circ_0007513	AACCATGCCTCCATCATCGA	GATTCTTGTGGATGCTCTGGG
hsa_circ_0021350	GCAACAGATCCAGGTACACC	TTCTGTTCATCATGCGCTGC
hsa_circ_0131934	CAACAAGCAATACAAGACCAAGT	GCTGTGCAGGAAAATAGAGCT
hsa_circ_0055954	CATCTTCTGGTTTCATTGGTTCA	GAAGGAGAGGGAGCTGGGTA
hsa_circ_0114014	GGGCAAAGGAGTATGGATGG	GACGGGGTCTGAAGGATCTT
hsa_circ_0078784	CCTGCTTGACAACCAAGTACTA	CTCCATGAAAACCGCTGCAT
hsa_circ_0092798	GACGGAGAGAGACAGCCTTT	TGAACCGACAGACCACGTAA

(Song X et al., 2016). This phenomenon might be due to the abundance of coding host genes, splicing factors and RNA binding proteins in the brain (Chen et al., 2016). CircRNAs may function as “miRNA sponge” (Tay et al., 2014), “protein sponge” (Schneider et al., 2016), transcriptional regulators (Li et al., 2015), and even coding sequences for peptides, indicating their potential as drug targets for cancer treatment (Wesselhoeft et al., 2018; Wu et al., 2020). An increasing number of researches have demonstrated the crucial roles of circRNAs in glioma progression. For example, circRNA MMP9 functions as a sponge to absorb miR-124 and thus promotes GBM progression (Wang et al., 2018). Meanwhile, circZNF292 promotes glioma proliferation and cell cycle progression (Yang et al., 2016). Likewise, circ-U2AF1 sponges hsa-miR-7-5p to derepress NOVA2 and thus augments glioma malignancy (Li et al., 2018). Moreover, circRNAs could be potential biomarkers for diagnosis and prognosis of GBM (Zhu et al., 2017; Li et al., 2018; Li et al., 2018). Interestingly, the abundance of most circRNAs is much lower in gliomas than in normal brain tissues (Westholm et al., 2014; Song et al., 2016), indicating that circRNAs may function as tumor suppressors, which has not been elucidated so far.

In this study, using bioinformatic methods, we identified circLRRC7 as the most dramatically downregulated circRNA in GBM and predicted miR-1281 and PDXP as the downstream genes of circLRRC7. The expression of circLRRC7 in GBMs vs. normal brains was validated and the correlation between circLRRC7, miR-1281 and PDXP was confirmed in GBM patients. These findings suggest a novel tumor suppressive circRNA and shed light on new therapeutic strategies for GBM treatment.

MATERIAL AND METHODS

Acquisition of Clinical Specimens and qRT-PCR

28 GBM specimens and 23 normal brain tissues were obtained from patients who received surgery at The First Affiliated Hospital of the University of Science and Technology of China (USTC) from 2019 to 2020. As to the normal brain tissues, 3 samples were GBM adjacent surgical margin (paired samples), and the rest 20 samples were from epilepsy patients. This study was approved by the Ethics Committee of The First Affiliated Hospital of USTC. Informed consent was acquired from each patient. The clinical, surgical, imaging and pathological records were reviewed retrospectively. The pathological diagnosis was validated by two pathologists independently. The survival time was

calculated from the date of diagnosis of GBM until October 16, 2020. The expression of potential circRNAs, miRNAs and mRNAs in resected tissues was tested through qRT-PCR. The primers used in this study were synthesized by Sangon Biotech.Ltd. (Shanghai, China) (Table 1). QRT-PCR was set at an initial denaturation step of 10 min at 95°C and 95°C for 10 s, 60°C for 20 s, and 72°C for 10 s for a total of 40 cycles. The relative circRNAs expression levels were normalized to GAPDH.

Statistical Analysis

Chi-square test and Fisher's test and plotting receiver operating characteristic curves (ROCs) was used to analyze relevant factors by SPSS20.0 (SPSS, Inc., Chicago). The Kaplan-Meier method was employed in estimating the survival rate. The Cox proportional hazards regression analysis was used in evaluating multivariate prognosis factors by SPSS20.0. Relation for circRNA-miRNA, miRNA-mRNA and circRNA-mRNA was performed by Person correlation coefficient using Graphpad Prism software (version 9). Results were regarded as statistically significant when p -value < 0.05.

Datasets Collection


The circRNA dataset in this study was obtained from NCBI GEO database (<http://www.ncbi.nlm.nih.gov/>) GSE147352 (15 normal brain tissues and 18 gliomas). The miRNA expression dataset derived from GEO GSE158284 (12 normal brain tissues and 20 gliomas) and mRNA expression profile were gained from TCGA database (<http://cancergenome.nih.gov/>), including 5 normal brain tissues and 169 gliomas.

Differential Expression Analysis of circRNAs, miRNAs and mRNAs

All raw data were normalized and log₂-transformed. The ID of the corresponding probe name was converted into gene symbols. We identified differentially expressed RNAs through R statistical software and the limma Bioconductor package. The criteria for screening differentially expressed circRNAs, miRNAs (DEmiRNAs) and mRNAs (DEmRNAs) was p -value < 0.05 and $|\log_2FC(\text{fold change})| > 1$.

Prediction of circRNAs-miRNAs-mRNAs Network

The Cancer-Specific circRNA (CSCD, <http://gb.whu.edu.cn/CSCD/>) and the circular RNA Interactome (<https://>



circinteractome.nia.nih.gov/) were used to get the overlapping target miRNAs (TmiRNAs) as candidate targets of the selected circRNAs. The common members of TmiRNAs and DE miRNAs were obtained the potential targeted miRNAs for further analyses.

The interactions between miRNAs and mRNAs were predicted through TargetScan (<http://www.targetscan.org>), miRDB (<http://www.mirdb.org/>) and miRATAR (<http://microna.gr/tarbase/>). Overlapping mRNAs called TmRNAs were picked up and further

TABLE 2 | The differentially expressed circRNAs with significance ($|\log_2FC| > 1$, p -value < 0.05) between normal brain and glioma tissues.

circRNA name	p-value	B	Log ₂ FC
hsa_circ_0073237	1.24E-35	105.0081668	5.284232218
hsa_circ_0024085	1.19E-08	3.615830329	4.63877503
hsa_circ_0009027	1.08E-06	3.750267651	4.576516122
hsa_circ_0007513	0.00011552	1.411585086	4.398741595
hsa_circ_0021350	1.63E-05	1.227686718	4.245986517
hsa_circ_0131934	3.54E-19	5.220663592	-5.616262636
hsa_circ_0055954	1.08E-10	4.342061264	-4.47807931
hsa_circ_0114014	6.58E-06	1.699945287	-3.987167056
hsa_circ_0078784	7.82E-12	5.253227992	-3.96307385
hsa_circ_0092798	9.34E-05	1.603328349	-3.913020024

intersected with DEmRNAs to obtain targeted mRNAs. The prognostic values of mRNAs in GBM were evaluated by Gliovis database (<http://gliovis.bioinfo.cnio.es/>) using Kaplan-Meier analysis.

Function Enrichment Analysis

The differentially expressed circRNAs were annotated with Circbase database (<http://circrna.org/>) to obtain informations of corresponding gene, then these genes were analyzed with Gene Ontology (GO) analysis. Differentially expressed mRNAs were studied with GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The function of circRNAs and mRNAs were presumed according to GO and KEGG analyses by using KOBAS website (<http://kobas.cbi.pku.edu.cn/kobas3/>).

RESULTS

Identification of circLRR7 as the Most Differentially Expressed circRNA in GBM

To detect the circRNAs specifically expressed in gliomas, we analyzed the GEO dataset (GSE147352) that determined the expression of all circRNAs in 15 normal brain tissues and 18 gliomas through high throughput sequencing. Among the 8,184 detected circRNAs, 38 upregulated circRNAs and 186 downregulated circRNAs were identified in gliomas in accordance with the criteria $|\log_2FC| > 1$, $p_{adj} < 0.05$ (**Figures 1A,B; Supplementary Table S1**). GO analysis showed that the differentially expressed circRNAs were significantly enriched in 8 GO categories, including nucleoplasm, cytoskeleton, postsynaptic density, membrane, cell junction, presynaptic membrane, ion channel binding and presynaptic active zone (**Figure 1C**). We picked up the top 5 up- and down-regulated circRNAs (**Table 2**) and tried to construct the circRNA-miRNA network through cytoscape software. Finally, we got the predicted circRNA-miRNA network for 8 circRNAs (hsa_circ_0073237, hsa_circ_0024085, hsa_circ_0009027, hsa_circ_007513, hsa_circ_0131934, hsa_circ_0055954, hsa_circ_0114014 and hsa_circ_0078784), whereas the rest 2 circRNAs (hsa_circ_0021350, and hsa_circ_0092798) were not able to be incorporated (**Figure 1D**). To investigate the expression pattern of these circRNAs in GBM, 3 pairs of samples of GBM and the

matched adjacent surgical margins from our hospital were employed for qRT-PCR analyses. Among the 6 validated circRNAs (hsa_circ_0024085, hsa_circ_0009027, hsa_circ_007513, hsa_circ_0131934, hsa_circ_0114014 and hsa_circ_0092798) with consistent expression patterns in qRT-PCR and the RNA-sequencing, hsa_circ_0114014 (circLRR7) demonstrated the most obvious downregulation in GBM samples (**Figures 1E,F**), suggesting an important role of this circRNA in GBM.

More samples (25 GBM and 20 normal brain tissue from epilepsy patients) from our hospital were used to examine the expression of circLRR7 and its association with clinicopathologic characteristics. Indeed, circLRR7 was strongly downregulated in GBM (relative fold change > 7 , $p < 0.0001$) (**Figure 2A**). When the GBM patients were stratified into the circLRR7-high and circLRR7-low groups by using the median circLRR7 level as the cut-off, no significant relationship was identified between circLRR7 expression and the age, gender, tumor size, KPS score, tumor location or IDH mutation status of the patients (**Table 3**). In contrast, higher circLRR7 expression was strongly associated with better 1-year progressive-free survival (PFS, $p = 0.011$) and 1-year overall survival (OS, $p = 0.011$) (**Table 3**). Consistently, Kaplan-Meier survival analysis showed that higher circLRR7 expression was significantly correlated with better PFS (median: high-19.4 m vs low-6.5 m, $p < 0.05$) and OS (median: high-20.9 m vs low-8.5m, $p < 0.05$) of the GBM patients (**Figures 2B,C**), suggesting that circLRR7 may function to alleviate GBM progression. To determine the values of different clinicopathological characteristics (age, gender and circLRR7 expression) on predicting prognosis, the ROC curves were plotted and the area under the ROC curve (AUC) larger than 0.7 was regarded as the threshold of a diagnostic discriminatory value. Only circLRR7 expression showed an AUC of 0.708, indicating its capacity to predict prognosis of GBM patients (**Figure 2D**). To further confirm the impact of circLRR7 on prognosis, the multivariate Meta-analysis was performed and the result indicated that the relative expression of circLRR7 was a protective factor for the survival of GBM patients, whereas other factors such as number of lesions, tumour size, KPS score, sex and age did not affect prognosis (**Figure 2E**). In summary, circLRR7 is the most significantly down-regulated circRNA in GBM with potential prognostic values.

Characterization of circLRR7

RNA-seq data showed that circLRR7 is derived from the exons 23–26 of the LRR7 gene and is transcribed into a 510nt circular RNA transcript (hsa_circ_0114014) in GBM (**Figure 3A**). We used forward primer for exon 26 and reverse primer for exon 23 of the LRR7 gene to perform PCR analysis. The band of circLRR7 was only detected by PCR using cDNA template transcribed with random Hexamer primers but not the oligo (dT) primers (**Figure 3B**), which confirmed the existence of circLRR7 as a novel circular RNA. PCR using the genomic DNA (gDNA) as template did not generate the band of circLRR7 (**Figure 3C**). Sanger sequencing of the PCR product confirmed the splice junction connecting exon 23 and




FIGURE 2 | Validation of circLRRC7 as an independent prognostic predictor of GBM. **(A)** The relative expression of circLRRC7 in 20 normal brain tissues and 25 GBM tissues. **(B,C)** Kaplan-Meier PFS **(B)** and OS **(C)** curves of GBM patients in correlation with circLRRC7 expression. **(D)** ROC to predict prognosis based on clinicopathology characters. Only circLRRC7 expression showed diagnostic discriminatory value as the area under the ROC curve (AUC) was 0.708 **(E)** Forest map indicated that confidence interval (CI) of circLRRC7 was <1, but CI of number of lesions, tumour size, KPS score, sex and age stretched across 1. (* $p < 0.05$; *** $p < 0.001$).

exon 26 of the LRRC7 gene (Figure 3D). These results confirmed the circLRRC7 as a circular RNA transcribed from the LRRC7 gene in GBM.

Identification of miR-1281 as a Potential Target of circLRRC7 in GBM

As most circRNAs function as miRNA sponges in tumors, we predicted target miRNAs of circLRRC7 by using the CSCD database and the CircInteractome database, resulting in 21 common miRNAs in the two databases (Supplementary Table


S2). After then, we screened for differentially expressed miRNAs (DEmiRNAs) in adult GBM and normal brain tissues by using GEO dataset (GSE158284) that determined the most differentially expressed miRNAs in 20 GBMs and 12 normal brain tissues (Figure 4A), resulting in 41 upregulated and 30 downregulated DEmiRNAs (Figure 4B; Supplementary Table S3). Intersection of the 21 potential target miRNAs of circLRRC7 and the 71 DEmiRNAs revealed hsa-miR-1281 as the only common miRNA with significant upregulation in GBM (Figure 4C). Furthermore, we determined the expression levels of miR-1281 in a batch of normal ($n = 15$) and GBM ($n = 18$)


TABLE 3 | Clinical characteristics of GBM patients with different circLRR7 expression.

Variable	Relative expression of circLRR7 [Number (% of total)]		p-value
	High	Low	
Age year	—	—	—
<55	6 (24)	5 (20)	0.695
≥55	6 (24)	8 (32)	—
Gender	—	—	—
Male	7 (28)	5 (20)	—
Female	5 (12)	8 (32)	0.434
Tumour Size	—	—	—
<5	7 (28)	7 (28)	—
≥5	5 (20)	6 (24)	1.000
KPS score	—	—	—
<80	2 (8)	4 (20)	1.000
≥80	10 (40)	9 (36)	—
Location	—	—	—
Frontal	2 (8)	6 (24)	0.293
Temporal	3 (12)	2 (8)	—
Insula	1 (4)	0 (0)	—
Central region	2 (8)	1 (4)	—
Multifoci	4 (16)	4 (16)	—
IDH	—	—	—
WT	10 (40)	13 (52)	0.220
Mutant	2 (8)	0 (0)	—
PFS	—	—	—
<1 year	5 (20)	12 (48)	0.011*
≥1 year	7 (28)	1 (4)	—
OS	—	—	—
<1 year	5 (20)	12 (48)	0.011*
≥1 year	7 (28)	1 (4)	—

Asterisks indicate statistical significance.

* $p \leq 0.05$.





tissues collected in our hospital. The results showed that miR-1281 was highly expressed in tumors relative to normal tissues (**Figure 4D**). Therefore, hsa-miR-1281 might be the potential target miRNA of circLRRC7 in GBM.


Analysis of Potential Target Genes of miR-1281 in GBM

miRNAs usually function by negatively regulating the expression of their target genes. We sought to identify the target mRNAs of hsa-miR-1281 via three databases (miRDB, miRTarBase and TargetScan) and found 97 candidate mRNAs (**Supplementary Table S4**). We then looked for differentially expressed mRNAs (DEmRNAs) in GBM relative to normal brain by analyzing the TCGA RNA-seq database (**Supplementary Table S5**), and found 1872 downregulated as well as 826 upregulated DEmRNAs (**Figures 5A,B**). Intersection of the 97 candidate mRNAs and the downregulated DEmRNAs resulted in 14 overlapping

mRNAs (PDXP, PDE1C, CACNA1G, C6orf106, DUSP8, SLC1A4, RTN2HRH3, MAFG, PPP2R2D, EGR3, FAM20B, STOX2, PRNP) (**Figure 5C**). KEGG pathway analysis demonstrated that these genes were significantly enriched in calcium signaling pathway, vitamin B6 metabolism, MAPK signaling pathway and so on (**Figure 5D**). In GO analysis, these genes were annotated to certain biological processes, cellular components and molecular functions, such as synapse, phosphoprotein phosphatase activity, cognition, phosphatase activity, dendrite, and dephosphorylation (**Figure 5E**). Therefore, miR-1281 as a potential target of circLRRC7 may be involved in regulation of several signaling pathways in GBM.


The Association Between circLRRC7, miR-1281, and PDXP in GBM

The expression of the 14 candidate miR-1281 target genes in GBM was further checked by analyzing the datasets of TCGA




Agilent 4502-A platform microarray assays. The results showed that 13 genes except for PDE1C were lowly expressed in GBM relative to normal brains with statistical significance (**Figure 6A-**

N). In addition, Kaplan-Meier survival analyses demonstrated that higher expression of PDXP, DUSP8, HRH3, and FAM20B was associated with better OS in GBM patients (**Figure 7A**).



CircRNAs as ceRNAs may function as miRNA sponges to offset miRNA-mediated mRNA inhibition. By using the Gliovis database, we found that PDXP among the four candidates was the only gene with a negative correlation with miR-1281 (Figure 7B). By using the same batch of samples as in

Figure 2A, we determined the expression levels of PDXP in normal and GBM tumor samples. The results showed that PDXP had a lower expression in tumor relative to normal tissues (Figure 7C). We further tried to determine the potential association between circLRR7, miR-1281 and PDXP in the



samples collected in our hospital. Among all samples collected in our hospital at different time points, simultaneous detection of circLRRC7, miR-1281 and PDXP was achieved in 15 samples. Lineage regression analyses revealed a negative correlation between circLRRC7 and miR-1281 (Figure 7D). Meanwhile, a

negative correlation was detected between miR-1281 and PDXP (Figure 7E). However, a positive correlation was detected between circLRRC7 and PDXP in these samples (Figure 7F). These data strongly suggest the association between circLRRC7, miR-1281 and PDXP in GBM progression.

DISCUSSION

Despite the advances in GBM treatment in the past decades, GBM is still a disease with a very high fatality rate (Okolie et al., 2016). GBM tumor cells demonstrate rapid proliferation and infiltrative growth, but the underlying mechanisms are yet unclear. Increasing evidence has indicated that circRNAs play important roles in physiological and pathophysiological processes in the central nervous system (Li et al., 2019). As the malignant brain tumor, GBM may have altered circRNA expression that may affect tumor development and progression. According to the cancer circRNA landscape through exome capture transcriptome sequencing, circRNAs may have diagnostic and therapeutic values in glioma (Vo et al., 2019). Nevertheless, there are very limited studies about the functions and mechanisms of circRNAs as tumor suppressors. In this study, by systematic analysis of existing databases, we detected circLRR7 as a tumor suppressor and proposed miR-1281 and PDXP as potential downstream genes of circLRR7 in GBM pathogenesis. High expression of circLRR7 was significantly associated with favorable PFS and OS in GBM patients. Moreover, meta-analysis revealed that circLRR7 was associated with prognosis of GBM in our study (Figure 2E). The tumor size and age showed no connection with prognosis (Figure 2E) probably due to the limited number of samples. More specimens are required for future studies about the impact of circLRR7 on the proliferation, apoptosis and invasiveness of GBM cells.

LRR7, the host gene of circLRR7, is a major component of the post-synaptic density (PSD) of excitatory synapses (Liu et al., 2013), and is reported to be associated with memory formation (Kim et al., 2020). We did not detect significantly altered LRR7 expression in GBM relative to normal brain tissues in the Gliovis database. However, our results showed that circLRR7 derived from LRR7 was distinctively downregulated in GBM tissues compared to normal brain samples. As circRNAs were derived from pre-mRNAs (Ashwal-Fluss et al., 2014), we predicted that splicing factors may participate in circLRR7 formation, but the detailed molecular mechanisms underlying the downregulation of circLRR7 in GBM required further exploration.

Plenty of evidence has shown that circRNAs regulate the expression of target miRNAs by acting as molecular sponges (Zhong et al., 2016). We identified has-miR-1281 as a potential target miRNA of circLRR7. Hsa-miR-1281 was reported to be negatively regulated by linc-GIHCG in gastric cancer (Liu et al., 2019) and breast cancer (Fan et al., 2019). Hsa-miR-1281 was also found as a p53-responsive microRNA that targeted USP39 to inhibit the survival of human osteosarcoma cells under ER stress (Jiang et al., 2018). Although these previous studies demonstrated the down-regulation of miR-1281 in breast and gastric cancers, we detected the upregulation of miR-1281 in GBM samples, indicating the different roles of miR-1281 in different tumors. Such difference may rely on the specific downstream target of microRNAs. We predicted PDXP as a potential downstream target of miR-1281 in GBM, which was supported by the fact that the expressions of PDXP and miR-1281 were negatively correlated. PDXP had never been associated with miR-1281 in

other cancers, and the tumorigenic functions of miR-1281 in GBMs may rely on PDXP.

Through systematic analysis of a series of databases, we connected circLRR7 to has-MIR-1281 and PDXP in GBM. Previous studies reported that monoallelic PDXP (Pyridoxal phosphate phosphatase) loss frequently occurred in gliomas and the occurrence rate increased along with glioma grades. GBM patients with lower median PDXP expression levels had significantly shorter mean survival periods (Schulze et al., 2016). In addition, PDXP regulated active vitamin B6 levels and transcriptomic features of GBM cell lines cultured under non-adherent, serum-free conditions (Schulze et al., 2018), indicating a potential role of PDXP in tumor metabolism and cancer stem cells. Future studies will further unveil the roles of circLRR7, miR-1281, and PDXP in the development of GBM and verify the prognostic values of these genes in GBM patients.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of The First Affiliated Hospital of USTC. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

All authors contributed to the study conception and design. The first draft of the manuscript was written by XK. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. The role of each author in this paper as follows: Conceptualization: HW. Methodology: XK. Formal analysis and investigation: XK, RX, and WW. Data collection: XK, RX, MZ, YL, and ML. Writing—original draft preparation: XK. Writing—review and editing: WZ, XF, and HW. Funding acquisition: HW. Resources: HW. Supervision: HW and XF.

FUNDING

This work was supported by the Natural Science Foundation of Anhui Province (1908085MH281).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmolb.2021.743417/full#supplementary-material>

REFERENCES

- Ameratunga, M., Pavlakis, N., Wheeler, H., Grant, R., Simes, J., and Khasraw, M. (2018). Anti-angiogenic Therapy for High-Grade Glioma. *Cochrane database Syst. Rev.* 2018 (11), CD008218. doi:10.1002/14651858.CD008218.pub4
- Ashwal-Fluss, R., Meyer, M., Pamudurti, N. R., Ivanov, A., Bartok, O., Hanan, M., et al. (2014). circRNA Biogenesis Competes with Pre-mRNA Splicing. *Mol. Cell* 56 (1), 55–66. doi:10.1016/j.molcel.2014.08.019
- Chen, W., and Schuman, E. (2016). Circular RNAs in Brain and Other Tissues: A Functional Enigma. *Trends Neurosciences* 39 (9), 597–604. doi:10.1016/j.tins.2016.06.006
- Fan, L. Y., Shi, K. Y., Xu, D., Ren, L. P., Yang, P., Zhang, L., et al. (2019). LncRNA GIHCG Regulates microRNA-1281 and Promotes Malignant Progression of Breast Cancer. *Eur. Rev. Med. Pharmacol. Sci.* 23 (24), 10842–10850. doi:10.26355/eurrev_201912_19788
- Hsu, M.-T., and Coca-Prados, M. (1979). Electron Microscopic Evidence for the Circular Form of RNA in the Cytoplasm of Eukaryotic Cells. *Nature* 280 (5720), 339–340. doi:10.1038/280339a0
- Jeck, W. R., Sorrentino, J. A., Wang, K., Slevin, M. K., Burd, C. E., Liu, J., et al. (2013). Circular RNAs Are Abundant, Conserved, and Associated with ALU Repeats. *Rna* 19 (2), 141–157. doi:10.1261/rna.035667.112
- Jiang, J., Ma, B., Li, X., Jin, W., Han, C., Wang, L., et al. (2018). MiR-1281, a P53-Responsive microRNA, Impairs the Survival of Human Osteosarcoma Cells upon ER Stress via Targeting USP39. *Am. J. Cancer Res.* 8 (9), 1764–1774.
- Kim, C. H., Kim, S., Kim, S. H., Roh, J., Jin, H., and Song, B. (2020). Role of Densin-180 in Mouse Ventral Hippocampal Neurons in 24-hr Retention of Contextual Fear Conditioning. *Brain Behav/PMCID* 10 (12), e01891. doi:10.1002/brb3.1891
- Li, F., Ma, K., Sun, M., and Shi, S. (2018a). Identification of the Tumor-Suppressive Function of Circular RNA ITCH in Glioma Cells through Sponging miR-214 and Promoting Linear ITCH Expression. *Am. J. Transl Res.* 10 (5), 1373–1386.
- Li, G., Huang, M., Cai, Y., Yang, Y., Sun, X., and Ke, Y. (2018c). Circ-u2af1 Promotes Human Glioma via Derepressing Neuro-Oncological Ventral Antigen 2 by Sponging Hsa-Mir-7-5p. *J. Cell Physiol.*
- Li, G., Yang, H., Han, K., Zhu, D., Lun, P., and Zhao, Y. (2018b). A Novel Circular RNA, Hsa_circ_0046701, Promotes Carcinogenesis by Increasing the Expression of miR-142-3p Target ITGB8 in Glioma. *Biochem. biophysical Res. Commun.* 498 (1), 254–261. doi:10.1016/j.bbrc.2018.01.076
- Li, J., Huang, L., Li, Z., Zhong, X., Tai, S., Jiang, X., et al. (2019). Functions and Roles of Long Noncoding RNA in Cholangiocarcinoma. *J. Cell Physiol* 234 (10), 17113–17126. doi:10.1002/jcp.28470
- Li, Z., Huang, C., Bao, C., Chen, L., Lin, M., Wang, X., et al. (2015). Exon-intron Circular RNAs Regulate Transcription in the Nucleus. *Nat. Struct. Mol. Biol.* 22 (3), 256–264. doi:10.1038/nsmb.2959
- Liu, D.-C., Jow, G.-M., Chuang, C.-C., Peng, Y.-J., Hsu, P.-H., and Tang, C.-Y. (2013). Densin-180 Is Not a Transmembrane Protein. *Cell Biochem Biophys* 67 (2), 773–783. doi:10.1007/s12013-013-9570-3
- Liu, G., Jiang, Z., Qiao, M., and Wang, F. (2019). Lnc-GIHCG Promotes Cell Proliferation and Migration in Gastric Cancer through miR-1281 Adsorption. *Mol. Genet. Genomic Med.* 7 (6), e711. doi:10.1002/mgg3.711
- Okolie, O., Bago, J. R., Schmid, R. S., Irvin, D. M., Bash, R. E., Miller, C. R., et al. (2016). Reactive Astrocytes Potentiate Tumor Aggressiveness in a Murine Glioma Resection and Recurrence Model. *Neuonc* 18 (12), 1622–1633. doi:10.1093/neuonc/now117
- Schneider, T., Hung, L.-H., Schreiner, S., Starke, S., Eckhof, H., Rossbach, O., et al. (2016). CircRNA-protein Complexes: IMP3 Protein Component Defines Subfamily of circRNPs. *Sci. Rep.* 6, 31313. doi:10.1038/srep31313
- Schulze, M., Fedorchenko, O., Zink, T. G., Knobbe-Thomsen, C. B., Kraus, S., Schwinn, S., et al. (2016). Chronophin Is a Glial Tumor Modifier Involved in the Regulation of Glioblastoma Growth and Invasiveness. *Oncogene* 35 (24), 3163–3177. doi:10.1038/ncr.2015.376
- Schulze, M., Hutterer, M., Sabo, A., Hoja, S., Lorenz, J., Rothhammer-Hampl, T., et al. (2018). Chronophin Regulates Active Vitamin B6 Levels and Transcriptomic Features of Glioblastoma Cell Lines Cultured under Non-adherent, Serum-free Conditions. *BMC cancer* 18 (1), 524. doi:10.1186/s12885-018-4440-4
- Song, X., Zhang, N., Han, P., Moon, B.-S., Lai, R. K., Wang, K., et al. (2016). Circular RNA Profile in Gliomas Revealed by Identification Tool UROBORUS. *Nucleic Acids Res.* 44 (9), e87. doi:10.1093/nar/gkw075
- Tay, Y., Rinn, J., and Pandolfi, P. P. (2014). The Multilayered Complexity of ceRNA Crosstalk and Competition. *Nature* 505 (7483), 344–352. doi:10.1038/nature12986
- Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., and Olson, J. J. (2010). Exciting New Advances in Neuro-Oncology: the Avenue to a Cure for Malignant Glioma. *CA: a Cancer J. clinicians* 60 (3), 166–193. doi:10.3322/caac.20069
- Vo, J. N., Cieslik, M., Zhang, Y., Shukla, S., Xiao, L., Zhang, Y., et al. (2019). The Landscape of Circular RNA in Cancer. *Cell* 176 (4), 869–881. e13. doi:10.1016/j.cell.2018.12.021
- Wang, R., Zhang, S., Chen, X., Li, N., Li, J., Jia, R., et al. (2018). EIF4A3-induced Circular RNA MMP9 (circMMP9) Acts as a Sponge of miR-124 and Promotes Glioblastoma Multiforme Cell Tumorigenesis. *Mol. Cancer* 17 (1), 166. doi:10.1186/s12943-018-0911-0
- Wesselhoeft, R. A., Kowalski, P. S., and Anderson, D. G. (2018). Engineering Circular RNA for Potent and Stable Translation in Eukaryotic Cells. *Nat. Commun.* 9 (1), 2629. doi:10.1038/s41467-018-05096-6
- Westholm, J. O., Miura, P., Olson, S., Shenker, S., Joseph, B., Sanfilippo, P., et al. (2014). Genome-wide Analysis of drosophila Circular RNAs Reveals Their Structural and Sequence Properties and Age-dependent Neural Accumulation. *Cel Rep.* 9 (5), 1966–1980. doi:10.1016/j.celrep.2014.10.062
- Wu, P., Mo, Y., Peng, M., Tang, T., Zhong, Y., Deng, X., et al. (2020). Emerging Role of Tumor-Related Functional Peptides Encoded by lncRNA and circRNA. *Mol. Cancer* 19 (1), 22. doi:10.1186/s12943-020-1147-3
- Yang, P., Qiu, Z., Jiang, Y., Dong, L., Yang, W., Gu, C., et al. (2016). Silencing of cZNF292 Circular RNA Suppresses Human Glioma Tube Formation via the Wnt/ β -Catenin Signaling Pathway. *Oncotarget* 7 (39), 63449–63455. doi:10.18632/oncotarget.11523
- Zhong, Z., Lv, M., and Chen, J. (2016). Screening Differential Circular RNA Expression Profiles Reveals the Regulatory Role of circTCF25-miR-103a-3p/miR-107-CDK6 Pathway in Bladder Carcinoma. *Sci. Rep.* 6, 30919. doi:10.1038/srep30919
- Zhu, J., Ye, J., Zhang, L., Xia, L., Hu, H., Jiang, H., et al. (2017). Differential Expression of Circular RNAs in Glioblastoma Multiforme and its Correlation with Prognosis. *Translational Oncol.* 10 (2), 271–279. doi:10.1016/j.tranon.2016.12.006

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Kong, Xu, Wang, Zeng, Li, Lin, Zhou, Fu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.